A Prospective Randomized Open Label Phase III Study of Geftinib Versus Docetaxel as Second or Third Line Therapy in Patients with Advanced Non Small Cell Lung Cancer in Asian Indians

Autor:	Surender Beniwal, R.K. Nirban, Harvindra Singh Kumar, Sitaram Maharia, Satya Narayan, Akhil Kapoor, Narender Kumar, Shankar Lal Jakhar
Rok vydání:	2015
Předmět:	Oncology medicine.medical_specialty business.industry Third-line therapy Hematology medicine.disease Docetaxel Internal medicine medicine In patient Non small cell Open label business Lung cancer medicine.drug
Zdroj:	Annals of Oncology. 26:i29
ISSN:	0923-7534
DOI:	10.1093/annonc/mdv050.05
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::c6543f526c63c003e40b04bcc05db289 https://doi.org/10.1093/annonc/mdv050.05 Zobrazit plný text záznamu